PDMR Dealing / Grant of Share Options

RNS Number : 6823Y

Oxford BioDynamics PLC

14 May 2021

 

14 May 2021 

Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing / Grant of Share Options

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, announces that it has today granted a total of 1,632,798 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group employees, including 462,798 options to Chief Executive Officer, Dr Jon Burrows, 480,000 options to Chief Financial Officer, Paul Stockdale and 150,000 options to Chief Operating Officer, Thomas Guiel, who is a person discharging managerial responsibility. The options were granted under the Company's 2016 Employee Share Option Plan with an exercise price of £1 per share.

One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.

Following this grant, Dr Jon Burrows, Paul Stockdale and Thomas Guiel hold options over Ordinary Shares and are interested in Ordinary Shares as follows:

	Total number of options over Ordinary Shares	Ordinary Shares held
		Number	% of current issued share capital
Jon Burrows	1,388,396	Nil	-
Paul Stockdale	600,000	15,000	0.02
Thomas Guiel	150,000	Nil	-

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Jon Burrows
2	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:  GB00BD5H8572
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	462,798 ordinary shares at an exercise price of 100 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	14 May 2021
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Paul Stockdale
2	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:  GB00BD5H8572
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	480,000 ordinary shares at an exercise price of 100 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	14 May 2021
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Thomas Guiel
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:  GB00BD5H8572
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	150,000 ordinary shares at an exercise price of 100 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	14 May 2021
f)	Place of the transaction	Outside a trading venue

-Ends-

For further details please contact:

Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO	Tel: [phone]
Shore Capital - Nominated Adviser and Broker Advisory: Edward Mansfield / John More Broking: Fiona Conroy	Tel: [phone]
Instinctif Partners Melanie Toyne-Sewell / Agnes Stephens / Katie Duffell / Nathan Billis	Tel: [phone] [e-mail]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

In March 2021, the Company launched its first commercial prognostic test,  EpiSwitch ®   CST  (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery,  EpiSwitch® Explorer Array Kit . Its next product will be a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched later in 2021.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases. 

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia

For more information, please visit the Company's website ,  www.oxfordbiodynamics.com , or follow on  Twitter  or  LinkedIn .

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

Oxford BioDynamics is leveraging its technology to develop a pipeline of tests in a wide range of indications, such as immuno-oncology, neurodegenerative and autoimmune diseases, to follow its commercial  EpiSwitch ®   CST  (Covid Severity Test).

 

END

 

 

DSHGIGDUIUBDGBS